v3.26.1
Revenue, net - Narrative (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Dec. 31, 2025
Sep. 03, 2019
Disaggregation of Revenue [Line Items]            
Revenue, net $ 39,663,000 $ 25,881,000 $ 75,883,000 $ 46,282,000    
Contract with customer, liability 0   0   $ 0  
Reserve or allowance for doubtful accounts 0   0   0  
Arimoclomol Purchase Agreement            
Disaggregation of Revenue [Line Items]            
Recognized revenue 9,000,000.0 2,600,000 19,100,000 5,000,000.0    
Clawback liability 4,300,000 2,000,000.0 9,000,000.0 3,700,000    
Estimated reserve liability     18,600,000   15,300,000  
MIPLYFFA            
Disaggregation of Revenue [Line Items]            
Revenue, net 30,200,000 21,500,000 54,900,000 38,600,000    
OLPRUVA            
Disaggregation of Revenue [Line Items]            
Revenue, net 200,000 300,000 500,000 400,000    
License | AZSTARYS License Agreement            
Disaggregation of Revenue [Line Items]            
Recognized revenue 300,000 $ 1,200,000   $ 2,100,000    
Contract with customer, liability, revenue recognized, including opening balance     1,400,000      
Contract with customer, liability $ 0   $ 0   $ 0  
License | Commave Therapeutics SA | AZSTARYS License Agreement            
Disaggregation of Revenue [Line Items]            
Milestone payments           $ 590,000,000.0
License | Relief Therapeutics            
Disaggregation of Revenue [Line Items]            
Royalty percentage     10.00%